Vir Biotechnology, Inc. (VIR) is an American biotechnology company headquartered in San Francisco, California. It's a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases.
Vir has a broad portfolio of development programs that target hepatitis B virus (HBV), influenza A, human immunodeficiency virus (HIV) and tuberculosis (TB). Its primary strategy is centered on applying immune programming to develop effective therapies for challenging infectious diseases.
Founded by a group of esteemed scientific researchers, including Dr. Robert Taylor, a pioneer in the field of infectious diseases, Vir Biotechnology, Inc. was incorporated in 2016. Since then, the company has made significant progress in its quest to create a world free from the burden of infectious diseases.
The VIR stock is traded on the NASDAQ under the ticker "VIR". The company has prominently garnered attention due to its proactive response to the COVID-19 pandemic. It prioritized developing novel therapies and vaccines to help stem the global outbreak. This endeavour led to the development of VIR-7831 and VIR-7832, monoclonal antibodies against SARS-CoV-2, the virus that causes COVID-19. VIR-7831, in partnership with GlaxoSmithKline plc, has shown considerable promise in early trials.
On top of its COVID-19 efforts, Vir has ongoing partnerships with various companies and organizations like Visterra, Alnylam Pharmaceuticals, Brii Biosciences, and the Bill & Melinda Gates Foundation. These collaborations aim to advance Vir's mission of addressing the world's most severe infectious diseases.
Despite being a relatively new player in the biotech sector, VIR has gained a reputation for its robust scientific acumen and dedication to innovative solutions. The future for Vir Biotechnology Inc. looks promising as it continues to work on its diverse pipeline of treatments and vaccines, reinforcing its position as a leader in immunology and infectious diseases.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Engineers Gate Manager LP significantly reduced its stake in Vir Biotechnology (NASDAQ:VIR) by selling 121,964 shares, though institutional ownership remains high. Despite the sale, analyst sentiment for Vir Biotechnology is generally positive, with a "Moderate Buy" consensus and an average price target significantly above its current trading price. The company also surpassed its recent quarterly earnings and revenue estimates.
This article analyzes Vir Biotechnology Inc. (NYSE: VIR) using AI models, identifying a weak near-term sentiment despite long-term strength. It presents three institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also provides multi-timeframe signal strengths and key support and resistance levels for VIR.
WINTON GROUP Ltd significantly reduced its stake in Vir Biotechnology Inc. (NASDAQ:VIR) by 58.3% in the second quarter, selling over 214,000 shares. Despite this reduction, institutional ownership remains high at 65.32%, with major investors like BlackRock and ARCH Venture Management increasing their positions. Vir Biotechnology reported strong quarterly earnings, beating analyst estimates with an EPS of $0.47 and revenue of $238.95 million, maintaining a "Moderate Buy" consensus rating among analysts.
Legal & General Group Plc has initiated a new position in Vir Biotechnology, Inc. (NASDAQ:VIR), investing $2.76 million to acquire 270,875 shares, representing approximately 0.16% of the company. Institutional investors now own 65.32% of VIR. Despite a recent earnings beat with EPS of $0.47 against estimates of $0.33 and significant revenue growth, Vir Biotechnology remains unprofitable, with analysts projecting a full-year loss of $1.84 per share, and the stock currently holds a consensus "Moderate Buy" rating.
Vir Biotechnology, Inc. (NASDAQ:VIR) has received a "Moderate Buy" consensus rating from eight brokerage firms, with an average 12-month price target of $21.57. The company recently reported strong quarterly earnings, beating EPS estimates by $0.14 and significantly exceeding revenue expectations with a 19582.5% year-over-year increase. Institutional investors hold a substantial 65.32% of the stock, with several firms increasing their stakes.
Bank of New York Mellon Corp has acquired a new stake of 694,374 shares in Vir Biotechnology, Inc. (NASDAQ:VIR) valued at approximately $7.08 million, representing about 0.41% of the company. Institutional investors collectively own 65.32% of VIR, and analysts have a "Moderate Buy" consensus rating with an average price target of $21.57. Vir Biotechnology recently surpassed quarterly expectations with $0.47 EPS and $238.95 million in revenue.
Corient Private Wealth LP has invested $3.17 million in Vir Biotechnology, Inc. (NASDAQ:VIR) by purchasing 310,548 shares during the second quarter, making it approximately 0.18% of their holdings in the company. Institutional investors collectively own 65.32% of Vir’s stock. The company recently reported strong quarterly earnings, surpassing analyst estimates with revenues of $238.95 million and EPS of $0.47, and analysts currently have a "Moderate Buy" rating with an average price target of $21.57.
Vir Biotechnology (NASDAQ:VIR) recently hit a new 52-week high of $11.74, closing at $10.94, with institutional investors holding a significant portion of its shares. The company surpassed quarterly earnings expectations, reporting $0.47 EPS against an expected $0.33, and revenues of $238.95 million against a forecast of $135.88 million. Despite this, Vir Biotechnology remains unprofitable with a negative net margin of 638.88%, and analysts have a "Moderate Buy" consensus rating with an average price target of $21.57.